Cargando…
Teprotumumab in Clinical Practice: Recommendations and Considerations From the OPTIC Trial Investigators
Thyroid eye disease (TED) is a vision-threatening and debilitating condition that until very recently had no Food and Drug Administration (FDA)-approved medical therapies. Teprotumumab has recently been approved to treat TED. We aim to provide guidance for its use, based on the input of the US inves...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Journal of Neuro-Ophthalmology
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584196/ https://www.ncbi.nlm.nih.gov/pubmed/33417417 http://dx.doi.org/10.1097/WNO.0000000000001134 |